Caixin Deep Dive: Untangling AstraZeneca’s China Fraud Case

Nov.08.2024

The British pharmaceutical giant falsified patient test results to secure insurance coverage for its cancer drug in an effort to boost sales, but the alleged misconduct ended up benefiting some patients

00:00

00:00/00:00

Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story:

Cover Story: How AstraZeneca’s China Fraud Was About More Than Greed

Zhu Xi contributed to this podcast.

Share this article

Open WeChat and scan the QR code

MORE WAYS TO LISTEN